Starpharma Holdings (SPL.AX) Stock Price

Starpharma Holdings Price

ASX·CLOSED
0.74AUD-0.06 (-8.47 %)
Market closed

Revenue at Starpharma Holdings has contracted by 0.9% per year over the past 19 years to 5.85 M AUD. For Starpharma Holdings, the net margin of -170.8% is up versus -917.3% a few years ago. The consensus 12-month price target for Starpharma Holdings is 0.56 AUD, about 23.7% below where the stock trades today. Of 5 analysts, 4 rate the stock a buy — an overall Buy consensus. The stock trades about 568% above its 52-week low.

Starpharma Holdings stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Starpharma Holdings over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Starpharma Holdings stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Starpharma Holdings's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Starpharma Holdings Stock Price History
DateStarpharma Holdings Price
8/11/20260.74 AUD
8/10/20260.80 AUD
8/7/20260.79 AUD
8/6/20260.80 AUD
8/5/20260.80 AUD
8/4/20260.75 AUD
8/3/20260.75 AUD
7/31/20260.75 AUD
7/30/20260.75 AUD
7/29/20260.74 AUD
7/28/20260.75 AUD
7/27/20260.70 AUD
7/24/20260.69 AUD
7/23/20260.69 AUD
7/22/20260.69 AUD
7/21/20260.70 AUD
7/20/20260.71 AUD
7/17/20260.71 AUD
7/16/20260.73 AUD
7/15/20260.73 AUD
7/14/20260.75 AUD
7/13/20260.72 AUD
7/10/20260.74 AUD
7/9/20260.73 AUD
7/8/20260.71 AUD
7/7/20260.71 AUD
7/6/20260.73 AUD
7/3/20260.74 AUD
7/2/20260.71 AUD
7/1/20260.72 AUD
6/30/20260.70 AUD
6/29/20260.70 AUD
6/26/20260.70 AUD
6/25/20260.69 AUD
6/24/20260.70 AUD
6/23/20260.69 AUD
6/22/20260.69 AUD
6/19/20260.69 AUD
6/18/20260.70 AUD
6/17/20260.70 AUD
6/16/20260.69 AUD
6/15/20260.69 AUD
6/12/20260.68 AUD
6/11/20260.67 AUD
6/10/20260.70 AUD
6/9/20260.70 AUD
6/5/20260.75 AUD
6/4/20260.75 AUD
6/3/20260.75 AUD
6/2/20260.75 AUD
6/1/20260.73 AUD
5/29/20260.70 AUD
5/28/20260.68 AUD
5/27/20260.68 AUD
5/26/20260.67 AUD
5/25/20260.64 AUD
5/22/20260.62 AUD
5/21/20260.62 AUD
5/20/20260.61 AUD
5/19/20260.60 AUD
5/18/20260.55 AUD
5/15/20260.62 AUD
5/14/20260.66 AUD
5/13/20260.74 AUD
5/12/20260.75 AUD
5/11/20260.74 AUD
5/8/20260.72 AUD
5/7/20260.73 AUD
5/6/20260.74 AUD
5/5/20260.73 AUD
5/4/20260.74 AUD
5/1/20260.71 AUD
4/30/20260.73 AUD
4/29/20260.72 AUD
4/28/20260.70 AUD
4/27/20260.75 AUD
4/24/20260.72 AUD
4/23/20260.73 AUD
4/22/20260.73 AUD
4/21/20260.70 AUD
4/20/20260.68 AUD
4/17/20260.69 AUD
4/16/20260.68 AUD
4/15/20260.62 AUD
4/14/20260.54 AUD
4/13/20260.52 AUD
4/10/20260.51 AUD
4/9/20260.51 AUD
4/8/20260.50 AUD
4/7/20260.51 AUD
4/2/20260.50 AUD
4/1/20260.49 AUD
3/31/20260.47 AUD
3/30/20260.46 AUD
3/27/20260.47 AUD
3/26/20260.47 AUD
3/25/20260.46 AUD
3/24/20260.47 AUD
3/23/20260.46 AUD
3/20/20260.47 AUD
3/19/20260.46 AUD
3/18/20260.46 AUD
3/17/20260.47 AUD
3/16/20260.47 AUD
3/13/20260.41 AUD
3/12/20260.40 AUD
3/11/20260.41 AUD
3/10/20260.40 AUD
3/9/20260.38 AUD
3/6/20260.41 AUD
3/5/20260.40 AUD
3/4/20260.37 AUD
3/3/20260.40 AUD
3/2/20260.44 AUD
2/27/20260.46 AUD
2/26/20260.45 AUD
2/25/20260.49 AUD
2/24/20260.46 AUD
2/23/20260.49 AUD
2/20/20260.50 AUD
2/19/20260.49 AUD
2/18/20260.47 AUD
2/17/20260.48 AUD
2/16/20260.50 AUD
2/13/20260.49 AUD
2/12/20260.47 AUD
2/11/20260.49 AUD
2/10/20260.41 AUD
2/9/20260.40 AUD
2/6/20260.37 AUD
2/5/20260.40 AUD
2/4/20260.41 AUD
2/3/20260.42 AUD
2/2/20260.37 AUD
1/30/20260.38 AUD
1/29/20260.40 AUD
1/28/20260.34 AUD
1/27/20260.35 AUD
1/23/20260.35 AUD
1/22/20260.34 AUD
1/21/20260.37 AUD
1/20/20260.37 AUD
1/19/20260.37 AUD
1/16/20260.36 AUD
1/15/20260.37 AUD
1/14/20260.37 AUD
1/13/20260.37 AUD
1/12/20260.35 AUD
1/9/20260.38 AUD
1/8/20260.37 AUD
1/7/20260.34 AUD
1/6/20260.37 AUD
1/5/20260.35 AUD
1/2/20260.37 AUD
12/31/20250.36 AUD
12/30/20250.37 AUD
12/29/20250.37 AUD
12/24/20250.38 AUD
12/23/20250.37 AUD
12/22/20250.37 AUD
12/19/20250.32 AUD
12/18/20250.34 AUD
12/17/20250.35 AUD
12/16/20250.33 AUD
12/15/20250.35 AUD
12/12/20250.37 AUD
12/11/20250.37 AUD
12/10/20250.38 AUD
12/9/20250.39 AUD
12/8/20250.39 AUD
12/5/20250.40 AUD
12/4/20250.36 AUD
12/3/20250.37 AUD
12/2/20250.39 AUD
12/1/20250.38 AUD
11/28/20250.41 AUD
11/27/20250.38 AUD
11/26/20250.38 AUD
11/25/20250.41 AUD
11/24/20250.39 AUD
11/21/20250.38 AUD
11/20/20250.41 AUD
11/19/20250.41 AUD
11/18/20250.42 AUD
11/17/20250.42 AUD
11/14/20250.42 AUD
11/13/20250.41 AUD
11/12/20250.44 AUD
11/11/20250.38 AUD
11/10/20250.34 AUD
11/7/20250.33 AUD
11/6/20250.34 AUD
11/5/20250.33 AUD
11/4/20250.34 AUD
11/3/20250.35 AUD
10/31/20250.34 AUD
10/30/20250.35 AUD
10/29/20250.37 AUD
10/28/20250.34 AUD
10/27/20250.34 AUD
10/24/20250.32 AUD
10/23/20250.31 AUD
10/22/20250.31 AUD
10/21/20250.31 AUD
10/20/20250.29 AUD
10/17/20250.26 AUD
10/16/20250.28 AUD
10/15/20250.28 AUD
10/14/20250.27 AUD
10/13/20250.26 AUD
10/10/20250.28 AUD
10/9/20250.29 AUD
10/8/20250.31 AUD
10/7/20250.31 AUD
10/6/20250.34 AUD
10/3/20250.34 AUD
10/2/20250.33 AUD
10/1/20250.27 AUD
9/30/20250.25 AUD
9/29/20250.22 AUD
9/26/20250.22 AUD
9/25/20250.23 AUD
9/24/20250.22 AUD
9/23/20250.22 AUD
9/22/20250.22 AUD
9/19/20250.13 AUD
9/18/20250.13 AUD
9/17/20250.13 AUD
9/16/20250.13 AUD
9/15/20250.13 AUD
9/12/20250.12 AUD
9/11/20250.13 AUD
9/10/20250.13 AUD
9/9/20250.13 AUD
9/8/20250.14 AUD
9/5/20250.13 AUD
9/4/20250.13 AUD
9/3/20250.11 AUD
9/2/20250.11 AUD
9/1/20250.12 AUD
8/29/20250.13 AUD
8/28/20250.14 AUD
8/27/20250.13 AUD
8/26/20250.13 AUD
8/25/20250.13 AUD
8/22/20250.14 AUD
8/21/20250.14 AUD
8/20/20250.13 AUD
8/19/20250.13 AUD
8/18/20250.13 AUD
8/15/20250.14 AUD
8/14/20250.13 AUD
Access this data via the Eulerpool API
Get Free API Key

Starpharma Holdings Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2022
4.90 M AUD
-16.42 M AUD
-16.15 M AUD
Jan 1, 2023
4.21 M AUD
-15.77 M AUD
-15.64 M AUD
Jan 1, 2024
9.76 M AUD
-8.17 M AUD
-8.17 M AUD
Jan 1, 2025
5.85 M AUD
-9.99 M AUD
-9.99 M AUD
Jan 1, 2026 (e)
15.80 M AUD
-15.80 M AUD
-3.25 M AUD
Jan 1, 2027 (e)
24.00 M AUD
-24.00 M AUD
-834,359.20 AUD
Jan 1, 2028 (e)
37.50 M AUD
-37.50 M AUD
11.38 M AUD
Jan 1, 2029 (e)
55.00 M AUD
-55.00 M AUD
19.91 M AUD

Starpharma Holdings Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 13, 2026, 3:00 AM
 
REVENUEM AUD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM AUD
EBITM AUD
EBIT MARGIN%
NET INCOMEM AUD
NET INCOME GROWTH%
SHARESM
2014201520162017201820192020202120222023202420252026e2027e2028e2029e
1.001.004.003.004.002.007.002.004.004.009.005.0015.0024.0037.0055.00
-50.00–300.00-25.0033.33-50.00250.00-71.43100.00–125.00-44.44200.0060.0054.1748.65
400.00400.00100.00133.33100.00100.0085.7150.0050.0075.00100.0080.0080.0080.0080.0080.00
4.004.004.004.004.002.006.001.002.003.009.004.0012.0019.2029.6044.00
-14.00-18.00-21.00-15.00-10.00-14.00-14.00-21.00-16.00-15.00-8.00-9.00-15.00-24.00-37.00-55.00
-1,400.00-1,800.00-525.00-500.00-250.00-700.00-200.00-1,050.00-400.00-375.00-88.89-180.00-100.00-100.00-100.00-100.00
-14.00-18.00-22.008.00-10.00-14.00-14.00-19.00-16.00-15.00-8.00-9.00-3.00–11.0019.00
180.0028.5722.22-136.36-225.0040.00–35.71-15.79-6.25-46.6712.50-66.67––72.73
284.41310.14345.04368.16370.14371.29372.23396.88406.90409.04411.43417.18417.18417.18417.18417.18
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Starpharma Holdings generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Starpharma Holdings retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Starpharma Holdings's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Starpharma Holdings has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Starpharma Holdings's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Starpharma Holdings stock margins

The Starpharma Holdings margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Starpharma Holdings. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Starpharma Holdings.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
63.23 %
-979.45 %
-917.34 %
Jan 1, 2022
43.34 %
-335.11 %
-329.74 %
Jan 1, 2023
73.38 %
-374.83 %
-371.63 %
Jan 1, 2024
93.52 %
-83.69 %
-83.69 %
Jan 1, 2025
79.08 %
-170.77 %
-170.77 %
Jan 1, 2026 (e)
79.08 %
-100.00 %
-20.58 %
Jan 1, 2027 (e)
79.08 %
-100.00 %
-3.48 %
Jan 1, 2028 (e)
79.08 %
-100.00 %
30.35 %

Starpharma Holdings Stock Revenue, EBIT, Earnings per Share

The Starpharma Holdings earnings per share therefore indicates how much revenue Starpharma Holdings has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
0.01 AUD
-0.05 AUD
-0.05 AUD
Jan 1, 2022
0.01 AUD
-0.04 AUD
-0.04 AUD
Jan 1, 2023
0.01 AUD
-0.04 AUD
-0.04 AUD
Jan 1, 2024
0.02 AUD
-0.02 AUD
-0.02 AUD
Jan 1, 2025
0.01 AUD
-0.02 AUD
-0.02 AUD
Jan 1, 2026 (e)
0.04 AUD
-0.04 AUD
-0.01 AUD
Jan 1, 2027 (e)
0.06 AUD
-0.06 AUD
-0.00 AUD
Jan 1, 2028 (e)
0.09 AUD
-0.09 AUD
0.03 AUD

Starpharma Holdings business model & stock analysis

Starpharma Holdings Ltd is an Australian company specializing in the development of innovative solutions in the fields of pharmacy and biotechnology. The company was founded in 1996 and has since written an impressive history full of successful developments and numerous partnerships. The main business of Starpharma focuses on the development and commercialization of drugs and other health products based on dendrimer technology. One of the most advanced applications of dendrimer technology is VivaGel, a topical gel for the prevention of sexually transmitted diseases, particularly HPV (Human Papillomavirus). VivaGel is based on a dendrimer that acts both as an antiviral agent and an antibiotic, capable of preventing infection by different types of HPV. The product has already undergone Phase III clinical trials and is currently being marketed worldwide. In addition to VivaGel, Starpharma also offers dendrimer-based technologies and services in the field of drug development. The company has formed numerous partnerships with major pharmaceutical companies such as AstraZeneca, GSK, and Merck, and is involved in the development of drugs for cancer, autoimmune diseases, and infectious diseases. Furthermore, Starpharma has expanded its dendrimer technology to other industries, such as agriculture, where dendrimers can contribute to improving soil quality and reducing pesticide use. In this sector, Starpharma has also formed partnerships with agricultural companies such as Adama and Nufarm. Overall, Starpharma is a company that has experienced significant growth in recent years and continues to focus on the development of new and innovative products and solutions. Its core competence in dendrimer technology has allowed it to establish itself as a key player in various industries and build numerous partnerships with global companies. With its diverse range of products and services and a strong focus on research and development, Starpharma can be considered an important player in the field of biotechnology and healthcare innovations. Indicate the sector in starpharma specialize in.

Starpharma Holdings SWOT Analysis

Strengths

Starpharma Holdings Ltd has several strengths that contribute to its success:

Starpharma develops and commercializes pharmaceutical products based on its proprietary dendrimer technology. The company's innovative approach allows for the development of highly effective drug delivery systems and unique therapeutic applications.

Starpharma's dedicated R&D team continuously works on expanding the applications of dendrimers, exploring new drug delivery methods, and enhancing the company's product portfolio. This commitment to innovation positions the company at the forefront of the industry.

Starpharma has established strategic partnerships with leading pharmaceutical companies, enabling it to access additional resources, expertise, and distribution channels. These partnerships enhance the company's market reach and accelerate product commercialization.

Weaknesses

Despite its strengths, Starpharma Holdings Ltd faces certain weaknesses:

The company's reliance on strategic partnerships can create potential vulnerabilities, as it may be subject to the decisions and strategies of its partners. Any changes or terminations in these partnerships could impact Starpharma's operations and financial performance.

While the company's dendrimer-based products have shown immense potential, Starpharma currently has a relatively limited product portfolio. Overreliance on a limited range of products can make the company vulnerable to changes in market demand or increased competition.

Opportunities

Starpharma Holdings Ltd can capitalize on the following opportunities:

The drug delivery market is expanding rapidly, driven by advancements in targeted and controlled drug release technologies. Starpharma's innovative dendrimer-based delivery systems position the company to seize a significant share of this market, particularly in specialized therapeutic areas.

The global demand for antiviral solutions, fueled by outbreaks such as the COVID-19 pandemic, presents an opportunity for Starpharma. The company's antiviral products, such as SPL7013, have potential applications in various antiviral fields, including personal hygiene, healthcare, and pandemic response.

Threats

Starpharma Holdings Ltd faces certain threats that could impact its business:

The pharmaceutical industry is highly regulated, and stringent regulations and compliance requirements can pose challenges for product development, clinical trials, and market approvals. Starpharma needs to navigate these regulatory hurdles effectively to ensure timely product commercialization.

The biotechnology and pharmaceutical sectors are competitive, with numerous companies vying for market share. Starpharma faces competition from both established players and emerging biotech firms. Sustaining a competitive advantage requires continuous innovation, marketing efforts, and maintaining strong intellectual property protection.

Starpharma Holdings Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Starpharma Holdings historical P/E ratio, EBIT multiple, and P/S ratio

Starpharma Holdings annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Starpharma Holdings shares outstanding

The number of shares of Starpharma Holdings was 417.18 M in 2025. This indicates how many shares Starpharma Holdings is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
396.88 M Stocks
Jan 1, 2022
406.90 M Stocks
Jan 1, 2023
409.04 M Stocks
Jan 1, 2024
411.43 M Stocks
Jan 1, 2025
417.18 M Stocks
Jan 1, 2026 (e)
417.18 M Stocks
Jan 1, 2027 (e)
417.18 M Stocks
Jan 1, 2028 (e)
417.18 M Stocks

Current Starpharma Holdings forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
80.00 % (4)
Hold
20.00 % (1)
Sell
0.00 % (0)
12M Price Target
0.56
Last Price
0.74
Currency
AUD
12M Return Potential
-23.67 %
LTM Return
0 %

EESG©

Eulerpool ESG Scorecard© for the Starpharma Holdings stock

58/100
39
Environment
99
Social
35
Governance
E

Environment

20
Scope 1 - Direct Emissions15.04
Scope 2 - Indirect emissions from purchased energy357.18
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions372.22
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees55
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Starpharma Holdings shareholder structure

% Name
7.15236%
Robmar Investments Pty Ltd
Robmar Investments Pty Ltd
2.96316%
UIL Limited
UIL Limited
2.86662%
FIL Investment Management (Hong Kong) Limited
FIL Investment Management (Hong Kong) Limited
2.80575%
Ingot Capital Investments Pty. Limited
Ingot Capital Investments Pty. Limited
0.62666%
ICM Limited
ICM Limited
0.01070%
DFA Australia Ltd.
DFA Australia Ltd.

Starpharma Holdings Beneficial Ownership Filings (SEC 13D/G)

Free Float
69.9%
Float Shares
-
Shares Outstanding
-

Starpharma Holdings Executives and Management Board

9 members · avg. age 63 · 22 % women

CM

Ms. Cheryl Maley

Chief Executive Officer, Managing Director, Director · since 2024

475,764.00 AUD

Management

JC

Mr. Justin Cahill

Chief Financial Officer, Company Secretary

464,158.00 AUD
JP

Dr. Jeremy Paull

Vice President - Development and Regulatory Affairs · since 2005

260,683.00 AUD
AE

Dr. A Tony Eglezos

Vice President - Business Development

249,700.00 AUD

Board of Directors

RT

Mr. Robert Thomas (78)

Independent Non-Executive Chairman of the Board

136,948.00 AUD
LC

Ms. Lynda Cheng

Independent Non-Executive Director

88,539.00 AUD
DM

Mr. David Mcintyre (52)

Independent Non-Executive Director

83,039.00 AUD
RB

Dr. Russell Basser

Independent Non-Executive Director

77,040.00 AUD
JD

Dr. Jeff Davies (59)

Independent Non-Executive Director

77,040.00 AUD

Starpharma Holdings Supply Chain

Starpharma Holdings Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
10 companies
#NameTrend
1
Humanwell Healthcare A
Supplier·Customer·Pharmaceuticals·CN
0.09
-0.61
0.20
0.77
0.83
0.65
2
Okamoto Industries
Supplier·Customer·Chemicals·JP
-0.47
0.20
0.53
0.68
0.77
0.35
#NameTrend
1
Aspen Pharmacare Holdings
Supplier·Customer·ZA
0.51
-0.43
—
—
—
—
2
AstraZeneca
Supplier·Customer·Pharmaceuticals·GB
-0.20
0.41
-0.17
-0.78
-0.73
-0.82
3
Merck & Co
Supplier·Customer·Pharmaceuticals·US
-0.35
-0.48
-0.49
-0.64
-0.63
-0.66
4
Tianjin Chase Sun Pharm A
Supplier·Customer·Pharmaceuticals·CN
0.23
-0.22
0.80
-0.32
-0.58
-0.55
5
HSBC Holdings
Supplier·Customer·Banks·GB
-0.43
0.18
-0.26
-0.79
-0.74
-0.40

Frequently asked questions about Starpharma Holdings

Starpharma Holdings Ltd is a leading pharmaceutical company, specializing in the development and commercialization of innovative products for the pharmaceutical, life-science, and biotechnology sectors. The company's business model revolves around creating value through the advancement of their proprietary drug delivery platforms, such as VivaGel and DEP, which enhance the efficacy and safety of a range of therapeutics. Starpharma Holdings Ltd also generates revenue by partnering with global pharmaceutical companies to license their technology. With a strong focus on research and development, Starpharma Holdings Ltd aims to revolutionize drug delivery systems and improve patient outcomes in various therapeutic areas, positioning itself as a leader in the pharmaceutical industry.

Starpharma Holdings Ltd is primarily active in the healthcare and pharmaceutical industries.

The main competitors of Starpharma Holdings Ltd in the market include other pharmaceutical companies such as Johnson & Johnson, Pfizer Inc., Novartis AG, and Merck & Co., Inc. These companies operate in similar industries and compete with Starpharma Holdings Ltd in areas such as research and development, product innovation, and market share. However, Starpharma Holdings Ltd stands out due to its unique expertise in dendrimer technology and the development of innovative pharmaceutical products.

Starpharma Holdings Ltd is a leading biopharmaceutical company with a rich history and background. Founded in 1996 and headquartered in Melbourne, Australia, Starpharma is focused on developing innovative pharmaceutical products and technologies. The company specializes in the design, development, and commercialization of dendrimer-based applications, particularly in the field of drug delivery and diagnostics. With a strong and experienced management team, Starpharma has achieved significant milestones and breakthroughs in the medical industry. The company's commitment to research and development has led to the creation of revolutionary products that address unmet medical needs. As Starpharma Holdings Ltd continues to grow and expand its portfolio, it remains a prominent player in the biopharmaceutical industry.

In recent years, Starpharma Holdings Ltd has achieved several significant milestones. The company successfully secured regulatory approvals for VivaGel®, its antiviral gel designed to prevent the transmission of HIV and genital herpes. Moreover, Starpharma forged an agreement with AstraZeneca, a leading pharmaceutical company, to explore the potential use of Starpharma's proprietary dendrimer technology in cancer treatment. Additionally, the company received strong market response for its VivaGel® products, leading to successful commercialization efforts and expanding its reach globally. Starpharma Holdings Ltd continues to make remarkable strides in the pharmaceutical industry through its innovative drug delivery and nanotechnology platforms.

Starpharma Holdings Ltd is primarily present in Australia.

Starpharma Holdings Ltd is a leading biopharmaceutical company driven by innovation and a commitment to improving lives through advanced pharmaceutical solutions. The company's core values revolve around scientific excellence, integrity, and a strong sense of social responsibility. With a focus on research and development, Starpharma strives to deliver breakthrough therapies and technologies in the fields of pharmaceuticals, personal care products, and agrochemicals. The corporate philosophy of Starpharma is centered on collaboration with partners and stakeholders to enhance patient outcomes and create value for shareholders. Through its dedication to transformative healthcare solutions, Starpharma is poised to revolutionize the industry and make a positive impact globally.

Analysts currently set an average price target of 0.56 AUD for the Starpharma Holdings stock (median: 0.56 AUD), implying -23.7 % versus the latest price. The consensus is based on 5 analyst ratings.

Starpharma Holdings Analyst Price Targets 2026

5 analysts currently rate the Starpharma Holdings stock: 4 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Starpharma Holdings to generate revenue of 15.80 M AUD and earnings per share of -0.01 AUD.

Starpharma Holdings Analyst Price Targets 2026

Converted at the current exchange rate, the Starpharma Holdings share trades at 0.45 EUR (0.74 AUD).

The Starpharma Holdings share (SPL.AX) is listed on 7 stock exchanges, including: Frankfurt (PQ6.F), München (PQ6.MU), Düsseldorf (PQ6.DU), Hamburg (PQ6.HM), SIX (Zürich) (PQ6.SW), ASX (SPL.AX).

Starpharma Holdings Ltd is an Australian biotechnology company based in Melbourne. The company operates in the fields of pharmaceuticals, biotechnology, and nanotechnology, focusing on the development and marketing of innovative technologies and medicines for the treatment of diseases. Its core areas of business include the development of micro-particles and polymers for artificial insemination, the development of virus and bacteria blockers for protection against sexually transmitted diseases, and the development of nano-antibodies for cancer treatment. Starpharma's products include VivaGel, a micro-particle foam used in artificial insemination, and Vivagel, a vaginal gel used as an effective measure against sexually transmitted diseases. The company also develops cancer drugs based on nanotechnology, such as DEP™, a patented technology for delivering cancer drugs using dendrimer nanoparticles. Starpharma has a partnership with AstraZeneca for the development and marketing of DEP™-based cancer drugs. The company's business model focuses on developing and marketing innovative technologies and medicines in the areas of artificial insemination, sexually transmitted diseases, and cancer treatment. The success of its business development depends on its ability to translate scientific advancements into tailored products, promote scientific progress through rapid innovation and global presence, and convince potential customers of the effectiveness of these products.

The expected revenue of Starpharma Holdings is 15.80 M AUD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Starpharma Holdings is -3.25 M AUD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Starpharma Holdings is currently -94.30. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Starpharma Holdings stock.

The price-to-sales ratio (P/S) of Starpharma Holdings is currently 19.41. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Starpharma Holdings stock.

The Eulerpool Quality Score for Starpharma Holdings is 4/10.

The ISIN of Starpharma Holdings is AU000000SPL0. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Starpharma Holdings is 796461. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Starpharma Holdings is SPL.AX. The ticker symbol is used to trade Starpharma Holdings shares on the stock exchange.

Starpharma Holdings paid dividends every year for the past 0 years.

Starpharma Holdings is assigned to the 'Health' sector.

The dividends of Starpharma Holdings are distributed in AUD.

All fundamentals and in-depth analysis of Starpharma Holdings

Our stock analysis for Starpharma Holdings stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Starpharma Holdings. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Starpharma Holdings Stock
Starpharma Holdings Revenue→
Starpharma Holdings Stock
Starpharma Holdings Net Income→
Starpharma Holdings Stock
Starpharma Holdings P/E→
Starpharma Holdings Stock
Starpharma Holdings P/S→
Starpharma Holdings Stock
Starpharma Holdings EBIT→
Starpharma Holdings Stock
Starpharma Holdings Dividend→
Starpharma Holdings Stock
Starpharma Holdings Directors Dealings→
Starpharma Holdings Stock
Starpharma Holdings Stocks→
Starpharma Holdings Stock
Starpharma Holdings Market capitalization→
Starpharma Holdings Stock
Starpharma Holdings Debt→
Starpharma Holdings Stock
Starpharma Holdings Liabilities→
Starpharma Holdings Stock
Starpharma Holdings Equity→
Starpharma Holdings Stock
Starpharma Holdings AAQS→
Starpharma Holdings Stock
Starpharma Holdings Employees→
Starpharma Holdings Stock
Starpharma Holdings ROE→
Starpharma Holdings Stock
Starpharma Holdings ROA→
Starpharma Holdings Stock
Starpharma Holdings ROCE→
Starpharma Holdings Stock
Starpharma Holdings News→
Starpharma Holdings Stock
Starpharma Holdings Analyst Price Targets→

Health Stocks

Statera BiopharmaStar Operating CompaniesStella PharmaStandard Chem & Pharm CoStem Cells SpinStandard BioToolsStem HoldingsStaidson (Beijing) BioPharmaceuticals CoStemCell InstituteSTAAR SurgicalStemRIMSt.Shine Optical CoAll Stocks A–Z →